Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cross-neutralization of distant coronaviruses correlates with Spike S2-specific antibodies from immunocompetent and immunocompromised vaccinated SARS-CoV-2-infected patients.
Patel SV, Leeman BM, Botros PJ, Folta J, Shahid D, Rocque AI, Joyal AS, Vecchio JA, Passell E, Tien D, Reynolds Z, Su K, Vyas TD, Vyas JM, Abar E, Barry M, Alexandrescu A, Wallace Z, DaCosta JM, Choudhary MC, Tamura T, Edelstein G, Li Y, Deo R, Sparks JA, Boucau J, Glover O, Barczak A, Lemieux J, Siedner MJ, Li JZ, Fofana IB. Patel SV, et al. Among authors: reynolds z. Res Sq [Preprint]. 2024 Dec 5:rs.3.rs-5487774. doi: 10.21203/rs.3.rs-5487774/v1. Res Sq. 2024. PMID: 39678346 Free PMC article. Preprint.
SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency.
Li Y, Choudhary MC, Regan J, Boucau J, Nathan A, Speidel T, Liew MY, Edelstein GE, Kawano Y, Uddin R, Deo R, Marino C, Getz MA, Reynolds Z, Barry M, Gilbert RF, Tien D, Sagar S, Vyas TD, Flynn JP, Hammond SP, Novack LA, Choi B, Cernadas M, Wallace ZS, Sparks JA, Vyas JM, Seaman MS, Gaiha GD, Siedner MJ, Barczak AK, Lemieux JE, Li JZ. Li Y, et al. Among authors: reynolds z. Sci Transl Med. 2024 Jan 24;16(731):eadk1599. doi: 10.1126/scitranslmed.adk1599. Epub 2024 Jan 24. Sci Transl Med. 2024. PMID: 38266109 Free PMC article.
Emerging SARS-CoV-2 Resistance After Antiviral Treatment.
Tamura TJ, Choudhary MC, Deo R, Yousuf F, Gomez AN, Edelstein GE, Boucau J, Glover OT, Barry M, Gilbert RF, Reynolds Z, Li Y, Tien D, Vyas TD, Passell E, Su K, Drapkin S, Abar EG, Kawano Y, Sparks JA, Wallace ZS, Vyas JM, Shafer RW, Siedner MJ, Barczak AK, Lemieux JE, Li JZ; POSITIVES Study Team. Tamura TJ, et al. Among authors: reynolds z. JAMA Netw Open. 2024 Sep 3;7(9):e2435431. doi: 10.1001/jamanetworkopen.2024.35431. JAMA Netw Open. 2024. PMID: 39320890 Free PMC article.
Duration of viable virus shedding in SARS-CoV-2 omicron variant infection.
Boucau J, Marino C, Regan J, Uddin R, Choudhary MC, Flynn JP, Chen G, Stuckwisch AM, Mathews J, Liew MY, Singh A, Lipiner T, Kittilson A, Melberg M, Li Y, Gilbert RF, Reynolds Z, Iyer SL, Chamberlin GC, Vyas TD, Goldberg MB, Vyas JM, Li JZ, Lemieux JE, Siedner MJ, Barczak AK. Boucau J, et al. Among authors: reynolds z. medRxiv [Preprint]. 2022 Mar 2:2022.03.01.22271582. doi: 10.1101/2022.03.01.22271582. medRxiv. 2022. Update in: N Engl J Med. 2022 Jul 21;387(3):275-277. doi: 10.1056/NEJMc2202092 PMID: 35262089 Free PMC article. Updated. Preprint.
Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variant.
Seaman MS, Siedner MJ, Boucau J, Lavine CL, Ghantous F, Liew MY, Mathews JI, Singh A, Marino C, Regan J, Uddin R, Choudhary MC, Flynn JP, Chen G, Stuckwisch AM, Lipiner T, Kittilson A, Melberg M, Gilbert RF, Reynolds Z, Iyer SL, Chamberlin GC, Vyas TD, Vyas JM, Goldberg MB, Luban J, Li JZ, Barczak AK, Lemieux JE. Seaman MS, et al. Among authors: reynolds z. JCI Insight. 2022 Oct 10;7(19):e159944. doi: 10.1172/jci.insight.159944. JCI Insight. 2022. PMID: 36214224 Free PMC article.
SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy.
Edelstein GE, Boucau J, Uddin R, Marino C, Liew MY, Barry M, Choudhary MC, Gilbert RF, Reynolds Z, Li Y, Tien D, Sagar S, Vyas TD, Kawano Y, Sparks JA, Hammond SP, Wallace Z, Vyas JM, Barczak AK, Lemieux JE, Li JZ, Siedner MJ. Edelstein GE, et al. Among authors: reynolds z. medRxiv [Preprint]. 2023 Jun 27:2023.06.23.23288598. doi: 10.1101/2023.06.23.23288598. medRxiv. 2023. Update in: Ann Intern Med. 2023 Dec;176(12):1577-1585. doi: 10.7326/M23-1756 PMID: 37425934 Free PMC article. Updated. Preprint.
SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational Study.
Edelstein GE, Boucau J, Uddin R, Marino C, Liew MY, Barry M, Choudhary MC, Gilbert RF, Reynolds Z, Li Y, Tien D, Sagar S, Vyas TD, Kawano Y, Sparks JA, Hammond SP, Wallace Z, Vyas JM, Barczak AK, Lemieux JE, Li JZ, Siedner MJ. Edelstein GE, et al. Among authors: reynolds z. Ann Intern Med. 2023 Dec;176(12):1577-1585. doi: 10.7326/M23-1756. Epub 2023 Nov 14. Ann Intern Med. 2023. PMID: 37956428 Free PMC article.
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance.
Phan T, Ribeiro RM, Edelstein GE, Boucau J, Uddin R, Marino C, Liew MY, Barry M, Choudhary MC, Tien D, Su K, Reynolds Z, Li Y, Sagar S, Vyas TD, Kawano Y, Sparks JA, Hammond SP, Wallace Z, Vyas JM, Li JZ, Siedner MJ, Barczak AK, Lemieux JE, Perelson AS. Phan T, et al. Among authors: reynolds z. bioRxiv [Preprint]. 2024 Sep 16:2024.09.13.613000. doi: 10.1101/2024.09.13.613000. bioRxiv. 2024. PMID: 39345409 Free PMC article. Preprint.
Duration of viral shedding and culture positivity with postvaccination SARS-CoV-2 delta variant infections.
Siedner MJ, Boucau J, Gilbert RF, Uddin R, Luu J, Haneuse S, Vyas T, Reynolds Z, Iyer S, Chamberlin GC, Goldstein RH, North CM, Sacks CA, Regan J, Flynn JP, Choudhary MC, Vyas JM, Barczak AK, Lemieux JE, Li JZ. Siedner MJ, et al. Among authors: reynolds z. JCI Insight. 2022 Jan 25;7(2):e155483. doi: 10.1172/jci.insight.155483. JCI Insight. 2022. PMID: 34871181 Free PMC article.
Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody Responses.
Seaman MS, Siedner MJ, Boucau J, Lavine CL, Ghantous F, Liew MY, Mathews J, Singh A, Marino C, Regan J, Uddin R, Choudhary MC, Flynn JP, Chen G, Stuckwisch AM, Lipiner T, Kittilson A, Melberg M, Gilbert RF, Reynolds Z, Iyer SL, Chamberlin GC, Vyas TD, Vyas JM, Goldberg MB, Luban J, Li JZ, Barczak AK, Lemieux JE. Seaman MS, et al. Among authors: reynolds z. medRxiv [Preprint]. 2022 Mar 3:2022.03.02.22271731. doi: 10.1101/2022.03.02.22271731. medRxiv. 2022. Update in: JCI Insight. 2022 Oct 10;7(19):e159944. doi: 10.1172/jci.insight.159944 PMID: 35262094 Free PMC article. Updated. Preprint.
43 results